Loading evaluation data…
Pain disorders such as neuropathic pain and headache remain areas of considerable unmet need and considered high risk by pharma. Human-induced pluripotent stem cells (iPSC)-derived sensory neurons have already been used to accelerate translational research but the current differentiation protocols produce non-peptidergic nociceptors. We demonstrate for the first time the robust differentiation of hiPSC into peptidergic nociceptor lineage with high yield. These nociceptors express CGRP and TRPV1 and show functional maturity including the expression of TTX-resistant currents and responding to TRPV1 and TRPA1 agonists. Importantly, they were able to release CGRP basally and upon stimulation by inflammatory soup, which was inhibited upon the application of the 5-HT1B/1D/1F agonist, sumatriptan, a migraine prophylactic drug. We report the successful generation of a novel in vitro functional peptidergic nociceptor model which will allow investigation of disease mechanisms in pain and translational phenotypic drug screening for new effective pain therapies.
they were able to release CGRP basally and upon stimulation by inflammatory soup, which was inhibited upon the application of the 5-HT1B/1D/1F agonist, sumatriptan
three-line ELISA pharmacology supports the direction, although independent differentiation structure and statistical detail remain underspecified
These nociceptors express CGRP and TRPV1 and show functional maturity including the expression of TTX-resistant currents and responding to TRPV1 and TRPA1 agonists.
TTX-resistant currents were observed in several of 15 cells but were not formally quantified
by co-culture with astrocytes, in vitro-derived TG early nociceptors can switch their fate from a non-peptidergic to peptidergic nociceptor type
co-culture shows CGRP features but lacks lineage tracing or exclusion of selective survival
Derived from the full evaluation — not a separate score.
Strengths
The cultures are evaluated using marker staining, a CALCA-GFP reporter, calcium imaging, patch clamp, CGRP ELISA, and scRNA-seq. This triangulation supports a peptidergic nociceptor-like phenotype more strongly than any single assay would.
↳ Results, Figures 2–5 and Figure S5–S7 references
Inflammatory-soup-evoked CGRP release and inhibition by sumatriptan or topiramate are reported across AH017-7, SBAD03-01, and SBAD02-01. Positive and negative secretory stimuli further contextualize the response.
↳ Results, Figures 3D and 4
The CGRP-release phenotype and response to established migraine treatments provide a direct rationale for follow-on disease-modeling and early drug-screening studies.
↳ Abstract; Discussion, CGRP pharmacology paragraph
Limitations
The 97.6% TRPV1/CGRP and 93.9% NEUN/CGRP estimates come from flow analysis of washed neurons from SBAD03-01, without a stated independent-run count. The scRNA-seq culture also contains fibroblast-like, pericyte-like, and glial populations.
↳ Results, flow-cytometry paragraph and Figure 5; STAR Methods, Flow Cytometry
Figure 3B/3C and Figure 6B/6C are assigned inconsistently between the Results and legends, and the Discussion cites a nonexistent Figure 3F. These defects make several assay results harder to locate reliably.
↳ Results and legends for Figures 3 and 6; Discussion, CGRP-release paragraph
Astrocyte co-culture produces CGRP expression and basal release, but no lineage tracing excludes selective survival or another compositional explanation. Evoked CGRP release is also absent in this condition.
↳ Introduction, final paragraph; Results and Discussion, astrocyte co-culture; Figure 6
The strongest evidence is the convergence of marker, reporter, imaging, electrophysiological, secretory, and transcriptomic observations, together with CGRP-release pharmacology across three iPSC lines. The score is held in the middle range because the 97.6% and 93.9% purity estimates are not accompanied by a clear independent-run count and derive from neurons washed away from the non-neuronal layer. Figure-panel mismatches and broad high-yield language further complicate verification and interpretation. The astrocyte experiment supports acquisition of peptidergic features, but its design does not establish a lineage-level fate switch.
Nabu’s assessment, alongside the field’s view.
Are you an author of this paper?
Sound3.4
Confidence mediumThe study meaningfully extends iPSC nociceptor methods by combining TG-like differentiation with CGRP secretion, drug modulation, and orthogonal molecular and functional characterization. Its novelty is qualified by cited prior peptidergic work and by the limited replication underlying the highest-yield estimate.
“inflammatory soup-evoked CGRP release was significantly inhibited in the presence of sumatriptan or topiramate in multiple wild-type lines”
Marker analysis, reporter validation, calcium imaging, electrophysiology, ELISA, and scRNA-seq provide convergent evidence, with pharmacology tested across three iPSC lines. Independent differentiation counts are unclear for key purity and imaging results, and randomization or blinded assessment is not reported for subjective outcomes.
“97.6% were TRPV1/CGRP double positive and 93.9% were NEUN/CGRP double positive”
The progression from differentiation strategy to identity, function, pharmacology, transcriptomics, and co-culture is coherent. Verification is hindered by Figure 3 and Figure 6 panel mismatches and by broad high-yield or fate-switch wording relative to the underlying designs.
“We can conclude that our protocol generates a highly pure culture of hiPSC-derived peptidergic nociceptors.”
The paper engages prior differentiation protocols, human and rodent nociceptor biology, and several assay-specific limitations. It less fully traces mixed-culture composition, rat–human co-culture, donor-line breadth, and assay qualification into the scope of translational claims.
“other factors may be required for evoked release”
Caveats4 of 4 checks
Repeated figure-panel mismatches make several results difficult to map to their supporting panels. The inconsistencies appear to be reporting defects rather than contradictions in the stated numerical results.
Informed consent, funding, competing interests, and a GEO accession are declared, and no supplied-text evidence indicates a conduct contradiction. These declarations are recorded without treating external verification as a reliability concern.
Flags: 3 declared / 5 total
77 references in manuscript 77 of 77 checkable references found in an index
No retraction notice found in Retraction Watch.
Sources: Retraction Watch ✓
Where this paper’s evidence sits on the path from initial observation to real-world use.
Sumatriptan and topiramate responses establish laboratory proof of concept for pharmacological use. Readiness remains preliminary because patient-derived lines, disease benchmarking, and screening-quality metrics are not reported.
AI-generated, human-governed. Something look off? Contact us to request a review.